On March 17, 2022, Amneal Pharmaceuticals of New York LLC received FDA approval for its Abbreviated New Drug Application (ANDA) #204857 for the generic version of the drug lacosamide, a widely prescribed anti-seizure medication. This clearance provides the brand-name drug with significant market competition, driving down prices and offering pharmaceutical payers a cost-effective alternative following the patent expiration.